Kevin Perez holds a MS in Computer Science from New York University (NYU) and a MS in Biomedical Sciences from Paris Descartes University. He is interested in biomedical data analysis and bringing the latest biomedical research news to patients.
Non-small cell lung cancer patients in England and Wales who failed prior chemotherapy can now access Opdivo (nivolumab) as a second-line treatment, following the therapy’s recent approval by the ... Read more
In just three years, Bristol-Myers Squibb (BMS) received more than 10 approvals for Opdivo (nivolumab), authored 12 publications in the New England Journal of Medicine, and was granted seven Breakthrough Therapy designations by ... Read more
The first patient has been dosed in a Phase 1b/2 trial evaluating Imugene’s stomach cancer vaccine HER-Vaxx. Researchers are still recruiting participants. They hope to enroll 18 patients at eight ... Read more
Bristol-Myers Squibb has formed a partnership with Japan’s Daiichi Sankyo to test Opdivo (nivolumab) in combination with DS-8201 in HER2-positive metastatic breast and bladder cancer. Opdivo, a blockbuster anti-PD-1 immune checkpoint inhibitor, is already ... Read more